Hypoimmune Anti-CD19 Chimeric Antigen Receptor T Cells Provide Lasting Tumor Control in Fully Immunocompetent Allogeneic Humanized Mice

Scientists generated human hypoimmune T cells with disrupted B2M, CIITA, and TRAC genes using CRISPR-Cas9 editing. In addition, CD47 and anti-CD19 CAR were expressed using lentiviral transduction.